MEDRx

MEDRx Co., Ltd. (株式会社メドレックス) is a Japanese pharmaceutical formulation development company headquartered in Higashikagawa, Kagawa Prefecture. Founded in January 2002, the company was established to develop new drug formulations suited to diversifying lifestyles and an unprecedented aging society. Its core focus is on transdermal absorption technology and other drug delivery systems that improve patient convenience and quality of life, particularly for patients who have difficulty with oral administration or who need to avoid missed doses. MEDRx's proprietary technology platforms include ILTS® (Ionic Liquid Transdermal System), which uses ionic liquids to dramatically enhance transdermal absorption, and NCTS® (Nano Colloid Transdermal System), which uses nano-colloids to improve skin penetration and reduce skin side effects. The company is also researching microneedle arrays for painless transdermal delivery of vaccines, nucleic acid drugs, and protein drugs that currently require injection. Its pipeline includes candidates such as MRX-4TZT, MRX-5LBT, MRX-9FLT, and MRX-6LDT. MEDRx obtained first- and second-class pharmaceutical manufacturing and sales licenses in April 2005 and launched its first product, Iodocoat ointment for pressure ulcers and skin ulcers, in August 2005. The company listed on the Tokyo Stock Exchange Mothers market in February 2013 and transitioned to the Growth Market in April 2022 following the exchange's market restructuring. It has established U.S. subsidiaries for clinical development, including IL Pharma Inc. (2007) and MEDRx USA INC. (2015), which merged in 2015. The current representative director and president is Yonehiro Matsumura. MEDRx positions itself as a formulation-focused R&D company aiming to deliver innovative new drugs to patients worldwide.

MEDRx Co., Ltd. was founded in January 2002 in Higashikagawa, Kagawa Prefecture, Japan, as a pharmaceutical formulation development company. Its founding mission was to develop new drug formulations responsive to diversifying lifestyles and the coming unprecedented aging society. In April 2005, the company obtained its first-class pharmaceutical manufacturing and sales license (No. 37A1X00003) and second-class license (No. 37A2X00006). In August 2005, it launched its first product, Iodocoat ointment, a treatment for pressure ulcers and skin ulcers. In August 2007, the company relocated its headquarters within Higashikagawa, from Matsubara to Nishiyama. In October 2007, it established IL Pharma Inc. in Massachusetts, USA, for clinical development in the United States. In February 2013, MEDRx listed on the Tokyo Stock Exchange Mothers market. In April 2015, it established MEDRx USA INC. in California, USA, also for U.S. clinical development. In October 2015, IL Pharma Inc. was absorbed into MEDRx USA INC. to centralize and streamline subsidiary management. In April 2022, following the Tokyo Stock Exchange's market restructuring, MEDRx transitioned from the Mothers market to the Growth market. The company continues to develop its proprietary transdermal technologies, including ILTS®, NCTS®, and microneedle arrays, and maintains a pipeline of drug candidates such as MRX-4TZT, MRX-5LBT, MRX-9FLT, and MRX-6LDT.

• 2022

  Transitioned from TSE Mothers to TSE Growth market

• 2015

  Established MEDRx USA INC. in California, USA

• 2015

  IL Pharma Inc. merged into MEDRx USA INC.

• 2013

  Listed on Tokyo Stock Exchange Mothers market

• 2007

  Relocated headquarters within Higashikagawa

• 2007

  Established IL Pharma Inc. in Massachusetts, USA

• 2005

  Obtained first-class and second-class pharmaceutical manufacturing and sales licenses

• 2005

  Launched Iodocoat ointment for pressure ulcers and skin ulcers

• 2002

  Founded in Higashikagawa, Kagawa, Japan

Formulation-focused R&D pharmaceutical company specializing in transdermal drug delivery to improve patient QOL.

• Iodocoat ointment

  Treatment for pressure ulcers and skin ulcers, launched in 2005.

• ILTS®

  Ionic Liquid Transdermal System that uses ionic liquids to dramatically enhance transdermal absorption.

• NCTS®

  Nano Colloid Transdermal System that uses nano-colloids to improve skin penetration and reduce skin side effects.

• Microneedle array

  Research and development of painless transdermal delivery systems for vaccines, nucleic acid drugs, and protein drugs.

1. 1株式会社メドレックス｜トップページmedrx.co.jp
2. 2会社沿革｜株式会社メドレックスmedrx.co.jp
3. 3企業情報｜株式会社メドレックスmedrx.co.jp
4. 4アクセス｜株式会社メドレックスmedrx.co.jp
5. 5MEDRx - Wikidatawikidata.org